Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Proprietary Prodrugs
100.0
%
| 10 | 100.0 % | 27 | 100.0 % | +162.58% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States and Europe
100.0
%
| 10 | 100.0 % | 27 | 100.0 % | +162.58% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Christal Mickle
FOU | Founder | 45 | 06-10-29 |
Neil McFarlane
CEO | Chief Executive Officer | 51 | 23-10-09 |
R. Clifton
DFI | Director of Finance/CFO | 51 | 15-03-31 |
Daniel Gallo
CTO | Chief Tech/Sci/R&D Officer | - | 23-01-30 |
Adrian Quartel
CTO | Chief Tech/Sci/R&D Officer | 63 | Jan. 03 |
Sven Guenther
CTO | Chief Tech/Sci/R&D Officer | 52 | 06-12-31 |
Nichol Ochsner
IRC | Investor Relations Contact | - | 22-08-08 |
Abbi Maher
LAW | General Counsel | - | 23-01-30 |
Joshua Schafer
PRN | Corporate Officer/Principal | 53 | 23-01-08 |
Comptroller/Controller/Auditor | 40 | 17-02-12 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Wendy Dixon
BRD | Director/Board Member | 68 | 23-04-24 |
Tamara Favorito
CHM | Chairman | 65 | 21-08-17 |
Director/Board Member | 56 | 23-04-24 | |
Christal Mickle
FOU | Founder | 45 | 06-10-29 |
Sven Guenther
CTO | Chief Tech/Sci/R&D Officer | 52 | 06-12-31 |
Corey Watton
BRD | Director/Board Member | 54 | 23-04-24 |
John Bode
BRD | Director/Board Member | 49 | 23-04-24 |
Thomas Anderson
BRD | Director/Board Member | 68 | 23-08-06 |
Alvin Shih
BRD | Director/Board Member | 47 | Jan. 19 |
Neil McFarlane
CEO | Chief Executive Officer | 51 | 23-10-09 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 45,001,878 | 39,916,898 ( 88.70 %) | 1,575,692 ( 3.501 %) | 88.70 % |
Company contact information
Zevra Therapeutics, Inc.
1180 Celebration Boulevard Suite 103
34747, Celebration
+321 939 3416
http://zevra.comSector
1st Jan change | Capi. | |
---|---|---|
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B | |
+3.90% | 1.65B |